Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Infusion of alloanergized donor lymphocytes after CD34-selected haploidentical myeloablative hematopoietic stem cell transplantation.

Davies JK, Brennan LL, Wingard J, Cogle CR, Kapoor N, Shah AJ, Dey BR, Spitzer TR, De Lima M, Cooper LJ, Thall P, Champlin RE, Nadler LM, Guinan EC.

Clin Cancer Res. 2018 May 16. pii: clincanres.0449.2018. doi: 10.1158/1078-0432.CCR-18-0449. [Epub ahead of print]

PMID:
29769208
2.

Phase I Trial of Brentuximab Vedotin for Steroid-Refractory Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.

DeFilipp Z, Li S, Kempner ME, Brown J, Del Rio C, Valles B, Hunnewell C, Saylor M, Vanderklish J, Dey BR, El-Jawahri A, McAfee SL, Spitzer TR, Chen YB.

Biol Blood Marrow Transplant. 2018 May 11. pii: S1083-8791(18)30264-7. doi: 10.1016/j.bbmt.2018.05.012. [Epub ahead of print]

PMID:
29758393
3.

Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity.

DeFilipp Z, Peled JU, Li S, Mahabamunuge J, Dagher Z, Slingerland AE, Del Rio C, Valles B, Kempner ME, Smith M, Brown J, Dey BR, El-Jawahri A, McAfee SL, Spitzer TR, Ballen KK, Sung AD, Dalton TE, Messina JA, Dettmer K, Liebisch G, Oefner P, Taur Y, Pamer EG, Holler E, Mansour MK, van den Brink MRM, Hohmann E, Jenq RR, Chen YB.

Blood Adv. 2018 Apr 10;2(7):745-753. doi: 10.1182/bloodadvances.2018017731.

4.

Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis.

Sun L, Li S, El-Jawahri A, Armand P, Dey BR, Fisher DC, Jacobsen ED, Jacobson CA, LaCasce AS, McAfee SL, Spitzer TR, Chen YB, DeFilipp Z.

Oncologist. 2018 May;23(5):624-630. doi: 10.1634/theoncologist.2017-0499. Epub 2017 Dec 28.

PMID:
29284757
5.

Neurologic complications after allogeneic hematopoietic stem cell transplantation: risk factors and impact.

Dowling MR, Li S, Dey BR, McAfee SL, Hock HR, Spitzer TR, Chen YB, Ballen KK.

Bone Marrow Transplant. 2018 Feb;53(2):199-206. doi: 10.1038/bmt.2017.239. Epub 2017 Nov 13.

PMID:
29131150
6.

Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies.

Khosla J, Yeh AC, Spitzer TR, Dey BR.

Bone Marrow Transplant. 2018 Feb;53(2):129-137. doi: 10.1038/bmt.2017.207. Epub 2017 Oct 2. Review.

PMID:
28967899
7.

Challenges to cervical cancer treatment in Bangladesh: The development of a women's cancer ward at Dhaka Medical College Hospital.

Haque N, Uddin AFMK, Dey BR, Islam F, Goodman A.

Gynecol Oncol Rep. 2017 Jun 27;21:67-72. doi: 10.1016/j.gore.2017.06.001. eCollection 2017 Aug. Review.

8.

Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.

Brunner AM, Li S, Fathi AT, Wadleigh M, Ho VT, Collier K, Connolly C, Ballen KK, Cutler CS, Dey BR, El-Jawahri A, Nikiforow S, McAfee SL, Koreth J, Deangelo DJ, Alyea EP, Antin JH, Spitzer TR, Stone RM, Soiffer RJ, Chen YB.

Br J Haematol. 2016 Nov;175(3):496-504. doi: 10.1111/bjh.14260. Epub 2016 Jul 19.

9.

Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years.

El-Jawahri A, Li S, Antin JH, Spitzer TR, Armand PA, Koreth J, Nikiforow S, Ballen KK, Ho VT, Alyea EP, Dey BR, McAfee SL, Glotzbecker BE, Soiffer RJ, Cutler CS, Chen YB.

Biol Blood Marrow Transplant. 2016 May;22(5):910-8. doi: 10.1016/j.bbmt.2015.12.024. Epub 2015 Dec 31.

10.

Association of acquired thrombotic thrombocytopaenic purpura in a patient with pernicious anaemia.

Podder S, Cervates J, Dey BR.

BMJ Case Rep. 2015 Oct 13;2015. pii: bcr2015211989. doi: 10.1136/bcr-2015-211989.

11.

Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia.

El-Jawahri A, Li S, Ballen KK, Cutler C, Dey BR, Driscoll J, Hunnewell C, Ho VT, McAfee SL, Poliquin C, Saylor M, Soiffer RJ, Spitzer TR, Alyea E, Chen YB.

Biol Blood Marrow Transplant. 2016 Jan;22(1):80-5. doi: 10.1016/j.bbmt.2015.08.001. Epub 2015 Aug 7.

12.

Quality of life and mood of patients and family caregivers during hospitalization for hematopoietic stem cell transplantation.

El-Jawahri AR, Traeger LN, Kuzmuk K, Eusebio JR, Vandusen HB, Shin JA, Keenan T, Gallagher ER, Greer JA, Pirl WF, Jackson VA, Ballen KK, Spitzer TR, Graubert TA, McAfee SL, Dey BR, Chen YB, Temel JS.

Cancer. 2015 Mar 15;121(6):951-9. doi: 10.1002/cncr.29149. Epub 2014 Dec 2.

13.

Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.

Chen YB, Li S, Lane AA, Connolly C, Del Rio C, Valles B, Curtis M, Ballen K, Cutler C, Dey BR, El-Jawahri A, Fathi AT, Ho VT, Joyce A, McAfee S, Rudek M, Rajkhowa T, Verselis S, Antin JH, Spitzer TR, Levis M, Soiffer R.

Biol Blood Marrow Transplant. 2014 Dec;20(12):2042-8. doi: 10.1016/j.bbmt.2014.09.007. Epub 2014 Sep 17.

14.

Engraftment syndrome after allogeneic hematopoietic cell transplantation in adults.

Omer AK, Kim HT, Yalamarti B, McAfee SL, Dey BR, Ballen KK, Attar E, Chen YB, Spitzer TR.

Am J Hematol. 2014 Jul;89(7):698-705. doi: 10.1002/ajh.23716. Epub 2014 Apr 10.

15.

Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation.

Yeh AC, Brunner AM, Spitzer TR, Chen YB, Coughlin E, McAfee S, Ballen K, Attar E, Caron M, Preffer FI, Yeap BY, Dey BR.

Biol Blood Marrow Transplant. 2014 May;20(5):730-4. doi: 10.1016/j.bbmt.2014.02.003. Epub 2014 Feb 12.

16.

Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies.

Brunner AM, Kim HT, Coughlin E, Alyea EP 3rd, Armand P, Ballen KK, Cutler C, Dey BR, Glotzbecker B, Koreth J, McAfee SL, Spitzer TR, Soiffer RJ, Antin JH, Ho VT, Chen YB.

Biol Blood Marrow Transplant. 2013 Sep;19(9):1374-80. doi: 10.1016/j.bbmt.2013.06.008. Epub 2013 Jun 18.

17.

Risk factors for invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a single center experience.

Omer AK, Ziakas PD, Anagnostou T, Coughlin E, Kourkoumpetis T, McAfee SL, Dey BR, Attar E, Chen YB, Spitzer TR, Mylonakis E, Ballen KK.

Biol Blood Marrow Transplant. 2013 Aug;19(8):1190-6. doi: 10.1016/j.bbmt.2013.05.018. Epub 2013 Jun 5.

18.

Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients.

Rosenblatt J, Avivi I, Vasir B, Uhl L, Munshi NC, Katz T, Dey BR, Somaiya P, Mills H, Campigotto F, Weller E, Joyce R, Levine JD, Tzachanis D, Richardson P, Laubach J, Raje N, Boussiotis V, Yuan YE, Bisharat L, Held V, Rowe J, Anderson K, Kufe D, Avigan D.

Clin Cancer Res. 2013 Jul 1;19(13):3640-8. doi: 10.1158/1078-0432.CCR-13-0282. Epub 2013 May 17.

19.

Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.

Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, Kapoor N, Pai SY, Rowley SD, Kebriaei P, Dey BR, Grilley BJ, Gee AP, Brenner MK, Rooney CM, Heslop HE.

Blood. 2013 Jun 27;121(26):5113-23. doi: 10.1182/blood-2013-02-486324. Epub 2013 Apr 22.

20.

Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.

Chen YB, Coughlin E, Kennedy KF, Alyea EP, Armand P, Attar EC, Ballen KK, Cutler C, Dey BR, Koreth J, McAfee SL, Spitzer TR, Antin JH, Soiffer RJ, Ho VT.

Biol Blood Marrow Transplant. 2013 Jun;19(6):981-7. doi: 10.1016/j.bbmt.2013.03.016. Epub 2013 Apr 2.

21.

Expression of α4β7 integrin on memory CD8(+) T cells at the presentation of acute intestinal GVHD.

Chen YB, McDonough S, Chen H, Kennedy J, Illiano C, Attar EC, Ballen KK, Dey BR, McAfee SL, Jagasia M, Soiffer R, Spitzer TR, Ritz J.

Bone Marrow Transplant. 2013 Apr;48(4):598-603. doi: 10.1038/bmt.2012.191. Epub 2012 Oct 8.

PMID:
23042495
22.

The expanding frontier of hematopoietic cell transplantation.

Spitzer TR, Dey BR, Chen YB, Attar E, Ballen KK.

Cytometry B Clin Cytom. 2012 Sep;82(5):271-9. doi: 10.1002/cyto.b.21034. Epub 2012 Aug 3. Review.

23.

Phase II trial of parathyroid hormone after double umbilical cord blood transplantation.

Ballen K, Mendizabal AM, Cutler C, Politikos I, Jamieson K, Shpall EJ, Dey BR, Attar E, McAfee S, Delaney C, McCarthy P, Ball ED, Kamble R, Avigan D, Maziarz RT, Ho VT, Koreth J, Alyea E, Soiffer R, Wingard JR, Boussiotis V, Spitzer TR, Antin JH.

Biol Blood Marrow Transplant. 2012 Dec;18(12):1851-8. doi: 10.1016/j.bbmt.2012.06.016. Epub 2012 Jul 2.

24.

Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant.

Ballen KK, Koreth J, Chen YB, Dey BR, Spitzer TR.

Blood. 2012 Mar 1;119(9):1972-80. doi: 10.1182/blood-2011-11-354563. Epub 2011 Dec 30. Review.

25.

Mechanisms of donor-specific tolerance in recipients of haploidentical combined bone marrow/kidney transplantation.

Andreola G, Chittenden M, Shaffer J, Cosimi AB, Kawai T, Cotter P, Locascio SA, Morokata T, Dey BR, Tolkoff-Rubin NT, Preffer F, Bonnefoix T, Kattleman K, Spitzer TR, Sachs DH, Sykes M.

Am J Transplant. 2011 Jun;11(6):1236-47. doi: 10.1111/j.1600-6143.2011.03566.x.

26.

High-dose chemotherapy with busulfan and cyclophosphamide and autologous stem cell rescue in patients with Hodgkin lymphoma.

Lane AA, McAfee SL, Kennedy J, Dube C, Attar EC, Ballen KK, Dey BR, Spitzer TR, Chen YB.

Leuk Lymphoma. 2011 Jul;52(7):1363-6. doi: 10.3109/10428194.2011.572324. Epub 2011 May 25. No abstract available.

27.

Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease.

Spitzer TR, Sykes M, Tolkoff-Rubin N, Kawai T, McAfee SL, Dey BR, Ballen K, Delmonico F, Saidman S, Sachs DH, Cosimi AB.

Transplantation. 2011 Mar 27;91(6):672-6. doi: 10.1097/TP.0b013e31820a3068.

28.

Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure.

Dey BR, Chung SS, Spitzer TR, Zheng H, Macgillivray TE, Seldin DC, McAfee S, Ballen K, Attar E, Wang T, Shin J, Newton-Cheh C, Moore S, Sanchorawala V, Skinner M, Madsen JC, Semigran MJ.

Transplantation. 2010 Oct 27;90(8):905-11. doi: 10.1097/TP.0b013e3181f10edb.

29.

Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.

Cortes J, Moore JO, Maziarz RT, Wetzler M, Craig M, Matous J, Luger S, Dey BR, Schiller GJ, Pham D, Abboud CN, Krishnamurthy M, Brown A Jr, Laadem A, Seiter K.

J Clin Oncol. 2010 Sep 20;28(27):4207-13. doi: 10.1200/JCO.2009.26.8896. Epub 2010 Aug 16.

30.

Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis.

Cutler C, Stevenson K, Kim HT, Brown J, McDonough S, Herrera M, Reynolds C, Liney D, Kao G, Ho V, Armand P, Koreth J, Alyea E, Dey BR, Attar E, Spitzer T, Boussiotis VA, Ritz J, Soiffer R, Antin JH, Ballen K.

Bone Marrow Transplant. 2011 May;46(5):659-67. doi: 10.1038/bmt.2010.192. Epub 2010 Aug 9.

31.

Donor-derived second hematologic malignancies after cord blood transplantation.

Ballen KK, Cutler C, Yeap BY, McAfee SL, Dey BR, Attar EC, Chen YB, Haspel RL, Liney D, Koreth J, Ho V, Alyea EP, Soiffer RJ, Spitzer TR, Antin JH.

Biol Blood Marrow Transplant. 2010 Jul;16(7):1025-31. doi: 10.1016/j.bbmt.2010.02.014. Epub 2010 Feb 21.

32.

von Willebrand disease type 2N: uncovering a congenital bleeding disorder in a patient with hepatitis C, cirrhosis, and coagulopathy.

Lane AA, Van Cott EM, Dey BR.

Am J Hematol. 2010 Feb;85(2):134-5. doi: 10.1002/ajh.21590. No abstract available.

33.

Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.

Ulrickson M, Aldridge J, Kim HT, Hochberg EP, Hammerman P, Dube C, Attar E, Ballen KK, Dey BR, McAfee SL, Spitzer TR, Chen YB.

Biol Blood Marrow Transplant. 2009 Nov;15(11):1447-54. doi: 10.1016/j.bbmt.2009.07.014. Epub 2009 Sep 1.

34.

Case records of the Massachusetts General Hospital. Case 28-2009. A 68-year-old man with fatigue, cough, and peripheral-blood monocytosis.

Dey BR, Spitzer TR, Hasserjian RP.

N Engl J Med. 2009 Sep 10;361(11):1099-106. doi: 10.1056/NEJMcpc0900641. No abstract available.

PMID:
19741232
35.

B-cell immunity in the context of T-cell tolerance after combined kidney and bone marrow transplantation in humans.

Porcheray F, Wong W, Saidman SL, De Vito J, Girouard TC, Chittenden M, Shaffer J, Tolkoff-Rubin N, Dey BR, Spitzer TR, Colvin RB, Cosimi AB, Kawai T, Sachs DH, Sykes M, Zorn E.

Am J Transplant. 2009 Sep;9(9):2126-35. doi: 10.1111/j.1600-6143.2009.02738.x. Epub 2009 Jul 16.

36.

Lineage switch of acute lymphocyctic leukaemia with t(4;11)(q21;q23) into acute myeloid leukaemia in an adult patient after allogeneic stem cell transplantation.

Trikalinos NA, Soupir CP, Dey BR.

Br J Haematol. 2009 Apr;145(2):262-4. doi: 10.1111/j.1365-2141.2009.07586.x. Epub 2009 Feb 4. No abstract available.

PMID:
19208102
37.

High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults.

Delaney M, Cutler CS, Haspel RL, Yeap BY, McAfee SL, Dey BR, Attar E, Kao G, Alyea EP, Koreth J, Ho VT, Saidman S, Liney D, Sese D, Soiffer RJ, Spitzer TR, Antin JH, Ballen KK.

Transfusion. 2009 May;49(5):995-1002. doi: 10.1111/j.1537-2995.2008.02077.x. Epub 2009 Jan 21.

38.

Clinical outcomes of late rather than early full-donor chimerism in patients with advanced lymphomas receiving nonmyeloablative allogeneic hematopoietic SCT.

Ting DT, Spitzer TR, Chaudhary A, Muzikansky A, Colby C, Power K, McAfee S, Ballen K, Attar E, Saidman SL, Preffer F, Sykes M, Dey BR.

Bone Marrow Transplant. 2008 Sep;42(5):329-35. doi: 10.1038/bmt.2008.167. Epub 2008 Jun 30.

PMID:
18587439
39.

Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation.

Haspel RL, Kao G, Yeap BY, Cutler C, Soiffer RJ, Alyea EP, Ho VT, Koreth J, Dey BR, McAfee SL, Attar EC, Spitzer T, Antin JH, Ballen KK.

Bone Marrow Transplant. 2008 Mar;41(6):523-9. Epub 2007 Nov 26.

40.

Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine.

Shaffer J, Villard J, Means TK, Alexander S, Dombkowski D, Dey BR, McAfee S, Ballen KK, Saidman S, Preffer FI, Sachs DH, Spitzer TR, Sykes M.

Exp Hematol. 2007 Jul;35(7):1140-52.

41.

Phase I trial of parathyroid hormone to facilitate stem cell mobilization.

Ballen KK, Shpall EJ, Avigan D, Yeap BY, Fisher DC, McDermott K, Dey BR, Attar E, McAfee S, Konopleva M, Antin JH, Spitzer TR.

Biol Blood Marrow Transplant. 2007 Jul;13(7):838-43. Epub 2007 Apr 30.

42.

Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen.

Dey BR, Shaffer J, Yee AJ, McAfee S, Caron M, Power K, Ting DT, Colby C, Preffer F, Ballen K, Attar E, Saidman S, Tarbell N, Sachs D, Sykes M, Spitzer TR.

Bone Marrow Transplant. 2007 Jul;40(1):19-27. Epub 2007 Apr 30.

PMID:
17468773
43.

Double unrelated reduced-intensity umbilical cord blood transplantation in adults.

Ballen KK, Spitzer TR, Yeap BY, McAfee S, Dey BR, Attar E, Haspel R, Kao G, Liney D, Alyea E, Lee S, Cutler C, Ho V, Soiffer R, Antin JH.

Biol Blood Marrow Transplant. 2007 Jan;13(1):82-9.

44.

Current status of haploidentical stem cell transplantation.

Dey BR, Spitzer TR.

Br J Haematol. 2006 Nov;135(4):423-37. Epub 2006 Sep 19. Review.

PMID:
16984391
45.

Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses.

Fudaba Y, Spitzer TR, Shaffer J, Kawai T, Fehr T, Delmonico F, Preffer F, Tolkoff-Rubin N, Dey BR, Saidman SL, Kraus A, Bonnefoix T, McAfee S, Power K, Kattleman K, Colvin RB, Sachs DH, Cosimi AB, Sykes M.

Am J Transplant. 2006 Sep;6(9):2121-33. Epub 2006 Jun 22.

46.

Role of Interferon-gamma in GVHD and GVL.

Yang YG, Wang H, Asavaroengchai W, Dey BR.

Cell Mol Immunol. 2005 Oct;2(5):323-9. Review.

47.

Cellular immune therapy for refractory cancers: novel therapeutic strategies.

Ballen KK, Colvin G, Dey BR, Porter D, Westervelt P, Spitzer TR, Quesenberry PJ.

Exp Hematol. 2005 Dec;33(12):1427-35. Review.

48.

Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation.

Dey BR, McAfee S, Colby C, Cieply K, Caron M, Saidman S, Preffer F, Shaffer J, Tarbell N, Sackstein R, Sachs D, Sykes M, Spitzer TR.

Br J Haematol. 2005 Feb;128(3):351-9.

PMID:
15667537
49.
50.

Interaction of 14-3-3 proteins with the insulin-like growth factor I receptor (IGFIR): evidence for a role of 14-3-3 proteins in IGFIR signaling.

Spence SL, Dey BR, Terry C, Albert P, Nissley P, Furlanetto RW.

Biochem Biophys Res Commun. 2003 Dec 26;312(4):1060-6.

PMID:
14651979

Supplemental Content

Support Center